Richardson, TX, April 18, 2019 --(PR.com
)-- Pillar Clinical Research (Pillar), with a focus on early and late stage CNS drug development, opens two new US research facilities in Illinois and Arkansas and adds Director of Quality Assurance.
Dr. Andrew Kim joined the Chicago team in September of 2018, and has spent over 5 years in clinical research and 10 years in clinical practice. He stated, “I am very excited to be part of the Pillar Clinical Research team in Chicago. We are humbled to be playing a role in helping advance medical research on potential cutting edge treatment options for psychiatric disorders and hope that we can be a vital resource for our surrounding communities in the Chicago area."
Dr. Fayz Hudefi joined Pillar in April of 2019 as Investigator at the Northwest Arkansas site. Dr. Hudefi says, “I believe that Pillar provides me with a great research platform to meet my personal goals of community service through bringing new medications to help those who struggle with various diseases.” Nichole Gutierrez, Site Director, echoes his sentiment, “I am so excited to continue the Pillar focus on participant care and research quality. Through our community partnerships, we look forward to emphasizing the importance of research to the future of mental health treatment, as well as decreasing the stigma of mental illness.”
Additionally, in the first quarter of 2019, Kristen Maxwell was added as the Director of Quality Assurance. She has extensive experience with IQVIA and is overseeing the harmonization and implementation of best practices across sites. Ms. Maxwell said of her role, “I joined Pillar Clinical Research after working in the clinical research industry for 18 years in different roles. I’m pleased I can fully utilize my unique perspective and organizational skill set within an industry leading research organization.”
CEO, Brian Craig, states, “We are finding our participant care and research excellence is attractive to many researchers as evidenced by our continued growth. Dr. Kim and Dr. Hudefi share our vision for human subject protection, scientific excellence, community focus, and have a proven track record of success. They strengthen our ability to offer the best clinical research resources at a local and national level. Furthermore, the addition Ms. Maxwell demonstrates our commitment to quality as a growing company in a dynamic industry. I am excited for the future of drug development.”
Pillar was originally founded in Texas 2006. The company has set itself apart through best in class research services as well as a focus on participant care, and the new facilities will carry on this tradition of excellence. Pillar is proud of a long history of collaboration with CROs, industry vendors, and clinical based technology providers. Please visit pillarcr.com to learn more about the organization and how they may be able to serve you!